Chinese start evaluation of Calypte HIV urine test
This article was originally published in Clinica
China's national centre for AIDS prevention and control has begun evaluating Calypte Biomedical's urine-based test system for HIV-1. The centre will assess the accuracy of the assay using Chinese patient samples and will recommend the introduction of a national testing programme if trials with the product are successful.
You may also be interested in...ï»¿
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.